Charles River Laboratories Gross Profit 2012-2026 | CRL
Charles River Laboratories annual/quarterly gross profit history and growth rate from 2012 to 2026. Gross profit can be defined as the profit a company makes after deducting the variable costs directly associated with making and selling its products or providing its services.
- Charles River Laboratories gross profit for the quarter ending June 30, 2026 was $0.363B, a 1.77% increase year-over-year.
- Charles River Laboratories gross profit for the twelve months ending June 30, 2026 was $1.307B, a 0.12% decline year-over-year.
- Charles River Laboratories annual gross profit for 2025 was $1.323B, a 0.64% decline from 2024.
- Charles River Laboratories annual gross profit for 2024 was $1.332B, a 11.36% decline from 2023.
- Charles River Laboratories annual gross profit for 2023 was $1.503B, a 2.73% increase from 2022.
|
Charles River Laboratories Annual Gross Profit (Millions of US $) |
|
|---|---|
| 2025 | $1,323 |
| 2024 | $1,332 |
| 2023 | $1,503 |
| 2022 | $1,463 |
| 2021 | $1,335 |
| 2020 | $1,074 |
| 2019 | $958 |
| 2018 | $840 |
| 2017 | $701 |
| 2016 | $644 |
| 2015 | $531 |
| 2014 | $473 |
| 2013 | $395 |
| 2012 | $392 |
| 2011 | $402 |
|
Charles River Laboratories Quarterly Gross Profit (Millions of US $) |
|
|---|---|
| 2026-06-30 | $363 |
| 2026-03-31 | $295 |
| 2025-12-31 | $310 |
| 2025-09-30 | $339 |
| 2025-06-30 | $357 |
| 2025-03-31 | $318 |
| 2024-12-31 | $284 |
| 2024-09-30 | $349 |
| 2024-06-30 | $354 |
| 2024-03-31 | $345 |
| 2023-12-31 | $364 |
| 2023-09-30 | $362 |
| 2023-06-30 | $399 |
| 2023-03-31 | $378 |
| 2022-12-31 | $399 |
| 2022-09-30 | $370 |
| 2022-06-30 | $357 |
| 2022-03-31 | $337 |
| 2021-12-31 | $347 |
| 2021-09-30 | $337 |
| 2021-06-30 | $342 |
| 2021-03-31 | $308 |
| 2020-12-31 | $300 |
| 2020-09-30 | $289 |
| 2020-06-30 | $232 |
| 2020-03-31 | $252 |
| 2019-12-31 | $262 |
| 2019-09-30 | $246 |
| 2019-06-30 | $238 |
| 2019-03-31 | $212 |
| 2018-12-31 | $226 |
| 2018-09-30 | $216 |
| 2018-06-30 | $216 |
| 2018-03-31 | $181 |
| 2017-12-31 | $167 |
| 2017-09-30 | $177 |
| 2017-06-30 | $185 |
| 2017-03-31 | $171 |
| 2016-12-31 | $177 |
| 2016-09-30 | $156 |
| 2016-06-30 | $170 |
| 2016-03-31 | $141 |
| 2015-12-31 | $141 |
| 2015-09-30 | $138 |
| 2015-06-30 | $133 |
| 2015-03-31 | $120 |
| 2014-12-31 | $120 |
| 2014-09-30 | $118 |
| 2014-06-30 | $126 |
| 2014-03-31 | $109 |
| 2013-12-31 | $88 |
| 2013-09-30 | $100 |
| 2013-06-30 | $103 |
| 2013-03-31 | $104 |
| 2012-12-31 | $91 |
| 2012-09-30 | $93 |
| 2012-06-30 | $104 |
| 2012-03-31 | $104 |
| 2011-12-31 | $101 |
| 2011-09-30 | $93 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical Services | $13.027B | $4.015B |
| Charles River Laboratories International, Inc. is a full service, early-stage contract research organization. The company provides essential products and services to help pharmaceutical and biotechnology companies, government agencies and leading academic institutions globally accelerate their research and drug development efforts. The company has a diverse portfolio of discovery and safety assessment services, both Good Laboratory Practice (GLP) and non-GLP. This helps support its clients from target identification through non-clinical development. Charles River also provides a line of products and services to support clients' manufacturing activities. Utilizing the company's broad portfolio of products and services, clients can create a more flexible drug development model, aiming cost reduction, productivity enhancement and increase in speed to market. Charles River currently has three reporting segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA) and Manufacturing Support. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Danaher (DHR) | United States | $147.177B | 25.78 |
| CVS Health (CVS) | United States | $120.850B | 12.05 |
| HCA Healthcare (HCA) | United States | $91.758B | 14.27 |
| Elevance Health (ELV) | United States | $90.552B | 14.21 |
| Cencora (COR) | United States | $61.693B | 18.85 |
| Natera (NTRA) | United States | $50.563B | 0.00 |
| Labcorp Holdings (LH) | United States | $26.274B | 18.52 |
| Viatris (VTRS) | United States | $19.124B | 6.61 |
| Medpace Holdings (MEDP) | United States | $17.319B | 36.37 |
| EUROFINS SCIENT (ERFSF) | Luxembourg | $16.369B | 0.00 |
| DiDi Global (DIDIY) | China | $16.046B | 176.00 |
| Revvity (RVTY) | United States | $15.643B | 26.20 |
| Solventum (SOLV) | United States | $15.330B | 12.69 |
| ICON (ICLR) | Ireland | $13.204B | 17.94 |
| BrightSpring Health Services (BTSG) | United States | $11.642B | 40.03 |
| Avantor (AVTR) | United States | $10.443B | 18.83 |
| BioMerieux (BMXMF) | France | $10.192B | 0.00 |
| Caris Life Sciences,�Inc (CAI) | United States | $8.054B | 79.17 |
| HealthEquity (HQY) | United States | $7.983B | 26.01 |
| Sonic Healthcare (SKHHY) | Australia | $6.771B | 0.00 |
| PACS (PACS) | United States | $6.662B | 22.39 |
| GETINGE (GNGBY) | Sweden | $6.654B | 18.79 |
| CochLear (CHEOY) | Australia | $6.327B | 0.00 |
| MiniMed (MMED) | United States | $6.193B | 0.00 |
| Bausch + Lomb (BLCO) | Canada | $6.157B | 23.28 |
| Sotera Health (SHC) | United States | $5.416B | 22.33 |
| Concentras Parent (CON) | United States | $4.542B | 22.40 |
| Organon (OGN) | United States | $3.587B | 4.55 |
| GeneDx Holdings (WGS) | United States | $2.822B | 262.89 |
| CareDx (CDNA) | United States | $2.723B | 309.65 |
| Amplifon S.p.A (AMFPF) | Italy | $2.466B | 12.74 |
| Pediatrix Medical (MD) | United States | $2.169B | 12.71 |
| Alignment Healthcare (ALHC) | United States | $2.151B | 54.58 |
| Establishment Labs Holdings (ESTA) | United States | $2.130B | 0.00 |
| Progyny (PGNY) | United States | $2.130B | 30.17 |
| COMPASS Pathways (CMPS) | United Kingdom | $1.912B | 0.00 |
| Sonida Senior Living (SNDA) | United States | $1.907B | 0.00 |
| Surgery Partners (SGRY) | United States | $1.787B | 68.25 |
| Bora Pharmaceuticals, - (BORAY) | Taiwan | $1.695B | 10.18 |
| Freenome (FRNM) | United States | $1.573B | 0.00 |
| Agilon Health (AGL) | United States | $1.547B | 0.00 |
| Ardent Health (ARDT) | United States | $1.508B | 8.62 |
| InnovAge Holding (INNV) | United States | $1.490B | 0.00 |
| Nutex Health (NUTX) | United States | $1.475B | 8.45 |
| Ryman Healthcare (RYHTY) | New Zealand | $1.241B | 0.00 |
| Omada Health (OMDA) | United States | $1.204B | 245.88 |
| GoodRx Holdings (GDRX) | United States | $1.196B | 23.27 |
| Teladoc Health (TDOC) | United States | $1.195B | 0.00 |
| CryoPort (CYRX) | United States | $0.826B | 0.00 |
| Enhabit (EHAB) | United States | $0.709B | 25.89 |
| GMR Solutions (GMRS) | United States | $0.688B | 0.00 |
| Oncology Institute (TOI) | United States | $0.507B | 0.00 |
| Charming Medical (MCTA) | Hong Kong, SAR China | $0.504B | 0.00 |
| SBC Medicals (SBC) | United States | $0.472B | 9.77 |
| Strata Critical Medical (SRTA) | United States | $0.468B | 0.00 |
| Forward Industries (FWDI) | United States | $0.449B | 0.00 |
| Auna S.A (AUNA) | Luxembourg | $0.382B | 5.55 |
| Shoulder Innovations (SI) | United States | $0.374B | 0.00 |
| Biodesix (BDSX) | United States | $0.292B | 0.00 |
| Embecta (EMBC) | United States | $0.288B | 2.50 |
| So-Young (SY) | China | $0.276B | 0.00 |
| LifeMD (LFMD) | United States | $0.164B | 0.00 |
| Ascend Wellness Holdings (AAWH) | United States | $0.107B | 0.00 |
| Park Dental Partners (PARK) | United States | $0.098B | 0.00 |
| SkinHealth Systems (SKIN) | United States | $0.088B | 0.00 |
| Sera Prognostics (SERA) | United States | $0.079B | 0.00 |
| QDM (QDMI) | Hong Kong, SAR China | $0.068B | 8.06 |
| Tevogen (TVGN) | United States | $0.050B | 0.00 |
| DocGo (DCGO) | United States | $0.038B | 0.00 |
| Lifeward (LFWD) | United States | $0.020B | 0.00 |
| SeaStar Medical Holding (ICU) | United States | $0.013B | 0.00 |
| NeuroOne Medical Technologies (NMTC) | United States | $0.013B | 0.00 |
| Ainos (AIMD) | United States | $0.010B | 0.00 |
| Basel Medical Group (BMGL) | Singapore | $0.008B | 0.00 |
| Co-Diagnostics (CODX) | United States | $0.008B | 0.00 |
| XWELL (XWEL) | United States | $0.008B | 0.00 |
| Aclarion (ACON) | United States | $0.008B | 0.00 |
| IceCure Medical (ICCM) | Israel | $0.007B | 0.00 |
| Intelligent Bio Solutions (INBS) | United States | $0.006B | 0.00 |
| 20/20 Biolabs (AIDX) | United States | $0.006B | 0.00 |
| Pheton Holdings (PTHL) | China | $0.006B | 0.00 |
| Pomdoctor - (POM) | China | $0.006B | 0.00 |
| BioNexus Gene Lab (BGLC) | $0.004B | 0.00 | |
| ISpecimen (ISPC) | United States | $0.003B | 0.00 |
| INVO Fertility (IVF) | United States | $0.002B | 0.00 |
| NewGenIvf Group (NIVF) | Thailand | $0.002B | 0.00 |
| Synergy CHC (SNYR) | United States | $0.001B | 0.00 |
| Cano Health (CANOQ) | United States | $0.000B | 0.00 |